Showing results (231-240 of 379) with videos related to
Sort By:
Pageof 38
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.Oncoimmunology|January 27, 2017
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinomaIsabel Poschke, Marta Faryna, Frank Bergmann, et al.Journal of Cancer Research and Clinical Oncology|May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspectiveKatharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.Melanoma Research|October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter studyJoshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.Cancer Immunology, Immunotherapy : CII|March 1, 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersKatharina C Kähler, Thomas K Eigentler, Anja Gesierich, et al.European Journal of Cancer (Oxford, England : 1990)|August 28, 2021
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesMarie-Luise Hilbers, Florentia Dimitriou, Peter Lau, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.Pageof 38